Prenatal screening for pre-eclampsia

Frequently asked questions

Research output: Contribution to journalReview ArticleOtherpeer-review

1 Citation (Scopus)

Abstract

The current approach to screening for pre-eclampsia is based on guidelines that rely on medical and obstetric history in early pregnancy to select a high-risk group that might benefit from low-dose aspirin. However, combined screening tests with the addition of biophysical and biochemical measurements have shown significantly better detection rates for preterm pre-eclampsia. Furthermore, the administration of aspirin for the 10% screen-positive group can lead to a significant reduction in severe and preterm forms of pre-eclampsia. This review aims to answer frequently asked questions related to the clinical implementation of screening and the management of screening results.

Original languageEnglish
Pages (from-to)477-483
Number of pages7
JournalAustralian and New Zealand Journal of Obstetrics and Gynaecology
Volume59
Issue number4
DOIs
Publication statusPublished - Aug 2019

Keywords

  • aspirin
  • hypertensive disorders in pregnancy
  • pre-eclampsia
  • prevention
  • screening

Cite this

@article{80cb55ac539f46dcb7f158855e5d4da7,
title = "Prenatal screening for pre-eclampsia: Frequently asked questions",
abstract = "The current approach to screening for pre-eclampsia is based on guidelines that rely on medical and obstetric history in early pregnancy to select a high-risk group that might benefit from low-dose aspirin. However, combined screening tests with the addition of biophysical and biochemical measurements have shown significantly better detection rates for preterm pre-eclampsia. Furthermore, the administration of aspirin for the 10{\%} screen-positive group can lead to a significant reduction in severe and preterm forms of pre-eclampsia. This review aims to answer frequently asked questions related to the clinical implementation of screening and the management of screening results.",
keywords = "aspirin, hypertensive disorders in pregnancy, pre-eclampsia, prevention, screening",
author = "Dagmar Wertaschnigg and Maya Reddy and Mol, {Ben W.J.} and Rolnik, {Daniel L.} and {da Silva Costa}, Fabricio",
year = "2019",
month = "8",
doi = "10.1111/ajo.12982",
language = "English",
volume = "59",
pages = "477--483",
journal = "Australian and New Zealand Journal of Obstetrics and Gynaecology",
issn = "0004-8666",
publisher = "Wiley-Blackwell",
number = "4",

}

Prenatal screening for pre-eclampsia : Frequently asked questions. / Wertaschnigg, Dagmar; Reddy, Maya; Mol, Ben W.J.; Rolnik, Daniel L.; da Silva Costa, Fabricio.

In: Australian and New Zealand Journal of Obstetrics and Gynaecology, Vol. 59, No. 4, 08.2019, p. 477-483.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Prenatal screening for pre-eclampsia

T2 - Frequently asked questions

AU - Wertaschnigg, Dagmar

AU - Reddy, Maya

AU - Mol, Ben W.J.

AU - Rolnik, Daniel L.

AU - da Silva Costa, Fabricio

PY - 2019/8

Y1 - 2019/8

N2 - The current approach to screening for pre-eclampsia is based on guidelines that rely on medical and obstetric history in early pregnancy to select a high-risk group that might benefit from low-dose aspirin. However, combined screening tests with the addition of biophysical and biochemical measurements have shown significantly better detection rates for preterm pre-eclampsia. Furthermore, the administration of aspirin for the 10% screen-positive group can lead to a significant reduction in severe and preterm forms of pre-eclampsia. This review aims to answer frequently asked questions related to the clinical implementation of screening and the management of screening results.

AB - The current approach to screening for pre-eclampsia is based on guidelines that rely on medical and obstetric history in early pregnancy to select a high-risk group that might benefit from low-dose aspirin. However, combined screening tests with the addition of biophysical and biochemical measurements have shown significantly better detection rates for preterm pre-eclampsia. Furthermore, the administration of aspirin for the 10% screen-positive group can lead to a significant reduction in severe and preterm forms of pre-eclampsia. This review aims to answer frequently asked questions related to the clinical implementation of screening and the management of screening results.

KW - aspirin

KW - hypertensive disorders in pregnancy

KW - pre-eclampsia

KW - prevention

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=85066841657&partnerID=8YFLogxK

U2 - 10.1111/ajo.12982

DO - 10.1111/ajo.12982

M3 - Review Article

VL - 59

SP - 477

EP - 483

JO - Australian and New Zealand Journal of Obstetrics and Gynaecology

JF - Australian and New Zealand Journal of Obstetrics and Gynaecology

SN - 0004-8666

IS - 4

ER -